Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security Strategic agreement will enable access to Moderna's respiratory vaccine portfolio as well as a technology transfer to Laboratorios Liomont for domestic manufacturing of Moderna's COVID-19 vaccine CAMBRIDGE, MA / ACCESS Newswire / February 10, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it has signed a Memorandum of Understanding (MoU) for a long-term ...

Moderna, Inc. (NASDAQ:MRNA) is one of the best healthcare stocks under $50 to invest in. Morgan Stanley reiterated a Hold rating on Moderna, Inc. (NASDAQ:MRNA) on February 2, setting a price target of $28.00. In a separate development, Moderna, Inc. (NASDAQ:MRNA) announced on January 29 a strategic collaboration with Recordati for the advancement of the former’s investigational propionic acidemia therapeutic, mRNA-3927, through the final stages of clinical development and global commercialization upon appr ...

Core Viewpoint - Moderna's stock has seen a significant increase of 39% year-to-date as of February 6, driven by positive developments in its clinical pipeline rather than its financial results, which are yet to be released for Q4 2025 [1][2]. Group 1: Clinical Developments - The rise in Moderna's shares is largely attributed to promising data from its personalized cancer vaccine candidate, mRNA-4157, developed in collaboration with Merck. Recent five-year data from a phase 2 trial showed a significant reduction in disease recurrence or death when mRNA-4157 was combined with Merck's Keytruda compared to Keytruda alone [4][5]. - Moderna's influenza vaccine candidate, mRNA-1010, has been submitted for regulatory approval for adults aged 50 and older. This vaccine performed well in phase 3 studies and aims to address the low efficacy of existing flu vaccines, which typically range from 40% to 60% [6]. Group 2: Financial Outlook - For the full year 2025, Moderna expects revenue between $1.6 billion and $2 billion, a decline from the $3.2 billion reported in 2024, largely due to reduced demand in the coronavirus vaccine market amid regulatory scrutiny [8]. - The upcoming earnings report is not expected to bring significant surprises, with revenue potentially closer to the lower end of guidance if market issues worsen. However, this is not anticipated to affect the company's long-term prospects significantly [9]. Group 3: Pipeline and Growth Potential - After facing inconsistent revenue and net losses, Moderna is making substantial progress in its pipeline, which could lead to a return to consistent top-line growth. The potential approval of mRNA-1010 and mRNA-4157 are seen as important catalysts for the company's future [10]. - Despite a significant decline in stock value over the past five years and potential clinical and regulatory setbacks, Moderna is considered a viable option for investors willing to accept some volatility [11].

Moderna (MRNA) closed at $41.95 in the latest trading session, marking a +2.29% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.47%. Meanwhile, the Dow experienced a rise of 0.04%, and the technology-dominated Nasdaq saw an increase of 0.9%. Coming into today, shares of the biotechnology company had gained 19.56% in the past month. In that same time, the Medical sector gained 2.92%, while the S&P 500 lost 0.16%. Investors will be eagerly watching for the performance o ...

Key Takeaways Moderna is expected to beat Q4 estimates, with sales projected at $661.4M and a loss of $2.60 per share.COVID-19 vaccines are expected to drive most sales, while the RSV vaccine mResvia faces tough competition.Investors await updates on intismeran studies and FDA resubmission plans for the COVID-flu combo vaccine.We expect Moderna (MRNA) to surpass expectations when it reports fourth-quarter and full-year 2025 results on Feb. 13, before the opening bell. The company’s earnings beat estimates b ...

Group 1 - The article provides a market analysis covering major indices such as S&P 500, Dow Jones Industrial Average, and US Small Cap 2000, along with a focus on Cisco Systems Inc [1] Group 2 - The analysis highlights the performance trends of the S&P 500 and Dow Jones, indicating fluctuations in market sentiment and investor confidence [1] - It discusses the implications of these trends for small-cap stocks, particularly in the context of economic recovery and growth potential [1] - Cisco Systems Inc is analyzed in terms of its market position and financial performance, reflecting broader industry trends [1]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：智通财经 1、经济数据方面，央行将于2月11日公布中国1月CPI和PPI。国家统计局2月13日将公布1月商品住宅销 售价格指数月度报告。国家统计局2月14日将发布流通领域重要生产资料市场价格变动情况。此外，中 国1月社融、1月新增人民币贷款等金融数据也将于下周公布。 2、国外经济数据方面，美国12月零售销售月率将于2月10日公布。美国1月失业率、美国1月非农就业人 口将于2月11日公布。英国第四季度GDP、美国1月PPI将于2月12日公布。欧元区第四季度GDP、美国1 月CPI将于2月13日公布。 3、美股财报季仍在持续中，下周有多家明星公司发布业绩，2月10日有：英国石油（盘前）、巴克莱银 行（盘前）、万豪酒店（盘前）、可口可乐（盘前）、阿斯利康（盘前）、福特汽车（盘后）、Lyft （盘后）、吉利德科学（盘后）；2月11日有：网易（盘前）、有道（盘前）、道达尔（盘前）、 Shopify（盘前）、思科（盘后）；2月12日有：猫途鹰（盘前）、凯悦酒店（盘前）、应用材料（盘 后）、淡水河谷（盘后）、Coinbase（盘后）、Rivia ...

The fourth quarter earnings season momentum continues this week, as results from Alphabet (GOOG, GOOGL), Amazon (AMZN), AMD (AMD), Qualcomm (QCOM), and Palantir (PLTR) highlighted the calendar. As of Feb. 6, 59% of S&P 500 (^GSPC) companies have reported fourth quarter results, according to FactSet data, and Wall Street analysts estimate a 13% increase in earnings per share for the fourth quarter. If that rate holds, it would represent the 10th consecutive quarter of annual earnings growth for the index a ...

Behind the household COVID-19 name, Moderna, is facing a $5 billion patent-infringement lawsuit over vaccine technology. On February 2, 2026, U.S. District Judge Joshua D. Wolson denied Moderna’s request for summary judgment, saying the jury will have the choice whether Moderna’s COVID-19 vaccine, Spikevax, breached on ‘lipid nanoparticle (LNP) technology’ originally patented by Genevant Sciences and Arbutus Biopharma. Judge Wolson used a “Star Trek” metaphor, saying that even with the US Government’s “ ...

Moderna (MRNA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this biotechnology company have returned +20.7%, compared to the Zacks S&P 500 composite's -1.5% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Moderna falls in, has gained 21.3%. The key question now is: What could be the stock's f ...